Heidrick & Struggles International, Inc. (NASDAQ:HSII – Get Free Report) declared a quarterly dividend on Monday, November 4th, RTT News reports. Shareholders of record on Thursday, November 14th will be paid a dividend of 0.15 per share by the business services provider on Thursday, November 21st. This represents a $0.60 annualized dividend and a yield of 1.50%.
Heidrick & Struggles International has a dividend payout ratio of 21.1% meaning its dividend is sufficiently covered by earnings. Analysts expect Heidrick & Struggles International to earn $2.85 per share next year, which means the company should continue to be able to cover its $0.60 annual dividend with an expected future payout ratio of 21.1%.
Heidrick & Struggles International Price Performance
Shares of NASDAQ HSII traded up $0.65 during mid-day trading on Monday, hitting $39.93. The company had a trading volume of 89,757 shares, compared to its average volume of 151,316. Heidrick & Struggles International has a 1-year low of $24.90 and a 1-year high of $41.94. The company has a market capitalization of $811.38 million, a PE ratio of 21.01, a price-to-earnings-growth ratio of 0.93 and a beta of 0.85. The business’s 50-day simple moving average is $37.90 and its 200 day simple moving average is $35.32.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on HSII
Heidrick & Struggles International Company Profile
Heidrick & Struggles International, Inc, together with its subsidiaries, provides executive search, consulting, and on-demand talent services to businesses and business leaders worldwide. It enables its clients to build leadership teams by facilitating the recruitment, management, and development of senior executives.
Recommended Stories
- Five stocks we like better than Heidrick & Struggles International
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Intel: Is Now the Time to Be Brave?
- Bank Stocks – Best Bank Stocks to Invest In
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Ride Out The Recession With These Dividend Kings
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Heidrick & Struggles International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heidrick & Struggles International and related companies with MarketBeat.com's FREE daily email newsletter.